Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day to sunitinib
at 50 mg/day in the treatment of patients with gastro-intestinal stromal tumor (GIST) after
progression with imatinib.